Benefits of early aggressive immunomodulatory therapy (tocilizumab and methylprednisolone) in COVID-19: Single center cohort study of 685 patients

INTRODUCTION: A growing evidence suggests that immune dysregulation and thrombotic phenomena are key features in the pathophysiology of COVID-19. Apart from antivirals and respiratory support, anticoagulants, corticoids and immunomodulators are increasingly being prescribed, especially for more seve...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:J Transl Autoimmun
Autors principals: Luis, Buzon-Martín, Miguel, Montero-Baladía, Pedro, Delgado-López, David, Iglesias-Posadilla, Itziar, Astigarraga, Ana, Galacho-Harriero, Enrique, Iglesias-Julián, María, López-Veloso, Noelia, De La Torre-Ferrera, Julio César, Barraza-Bengoechea, Marta, Ubeira- Iglesias, Rodrigo, San Llorente- Sebastián, María, Colazo-Burlato, Andrés, Lorenzo-Martín, Javier, Minguito de la Iglesia, Juan Pablo, García-Muñoz, Gerardo, Hermida-Fernández, Carolina, Navarro-San Francisco, Jorge, Boado-Lama, María, Fernández-Regueras, Fernando, Callejo-Torre, Sergio, Ossa-Echeverri, Lourdes, Fisac-Cuadrado, María, Gero-Escapa, Gregoria, Megías-Lobón, Adolfo, Simón-Rodríguez, José Antonio, Fernández-Ratero
Format: Artigo
Idioma:Inglês
Publicat: Elsevier 2021
Matèries:
Review article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC7879932/
https://ncbi.nlm.nih.gov/pubmed/33615209
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.jtauto.2021.100086
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars